Cybin Inc. CYBN Archives - Page 8 of 18

FridayApr 08, 2022 11:36 am

QualityStocksNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Further Strengthens Long-Term IP Position of Psychedelic-Based Programs

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” has announced that the World Intellectual Property Organization (“WIPO”) published an international patent application covering a range of inhalation delivery methods across multiple psychedelic molecules (Patent Cooperation Treaty (‘PCT’) patent application no.PCT/EP2021/077057). This further strengthens the company’s long-term intellectual property (“IP”) position of psychedelic-based programs. “The publication of this PCT patent application demonstrates our continued commitment to discovering and developing new psychedelic-based treatment options, in addition to identifying and combining potentially improved and well-controlled delivery systems with these clinical candidates,” said Cybin CEO Doug Drysdale.…

FridayApr 08, 2022 9:15 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Strengthening Foothold in Multibillion-Dollar Mental Health Space

Recent study forecasts global mental health market to reach almost $538B by 2030 One in five people in the United States deals with mental illness, including depression, anxiety, PTSD and more Cybin is moving three drug candidates forward, targeting major depressive, alcohol use and anxiety disorders A recent market study reports that the global mental health market, which was valued at $383.31 billion in 2020, is estimated to reach $537.97 billion by 2030, growing at a compound annual growth rate of 3.5% from 2021 to 2030 (https://ibn.fm/J7hfJ). With three active drug programs targeting mental-health disorders, Cybin (NEO: CYBN) (NYSE American: CYBN)…

WednesdayApr 06, 2022 12:39 pm

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Participate in Upcoming Benzinga Psychedelics Capital Conference

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be represented at the Benzinga Psychedelics Capital Conference. The premier event is scheduled for April 19, 2022, and will be held in Miami Beach, Florida. Cybin CEO Doug Drysdale will present a fireside chat and will also be a member of a panel discussion. Drysdale’s chat is slated to start at 1:10 p.m. ET. The panel discussion, which is titled “Short, Medium, and Long Term Catalysts in Psychedelics,” is scheduled for 3:10 p.m. ET. Archives versions of both events will be available on the company’s…

TuesdayApr 05, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Begins Recruitment for Study Measuring Ketamine’s Psychedelic Effect

Cybin-sponsored study will use Kernel Flow, Kernel’s quantitative neuroimaging. Company hopes to learn more about impact ketamine has on brain activity, overall mental well-being. Study results may lead to future studies supporting CYBN’s mission to develop psychedelics into therapeutics. Cybin’s (NEO: CYBN) (NYSE American: CYBN) efforts to transform the mental-health treatment landscape have reached a key milestone: the company is actively recruiting participants for its upcoming feasibility study using Kernel Flow, Kernel’s quantitative neuroimaging technology (https://ibn.fm/9aSxc). “The feasibility study using Kernel Flow offers an opportunity for researchers and our study participants to quantifiably gather information on a psychedelic experience,” said Cybin…

FridayApr 01, 2022 1:58 pm

QualityStocksNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) Adelia Therapeutics Inc. Achieves New Milestone

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that Adelia Therapeutics, a wholly controlled subsidiary of Cybin, has achieved the milestone identified as Year 1, Q2 (iv) as contemplated by the terms of a contribution agreement dated Dec. 4, 2020. The transaction agreement was among Cybin, Cybin Corp., Cybin US Holdings Inc. (the “acquiror”), a wholly-controlled subsidiary of Cybin, and all of the previous shareholders of Adelia. “We are extremely pleased with the rate and speed in which our team has been able to achieve these milestones that support our pipeline…

ThursdayMar 31, 2022 12:57 pm

QualityStocksNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Commencement of Kernel Flow(R) Feasibility Study, Marking Exciting Moment for Psychedelic Drug Development

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that the first visit has been conducted in a Cybin-sponsored feasibility study. The study will focus on evaluating Kernel’s quantitative neuroimaging technology, Flow, to measure ketamine’s psychedelic effects on cerebral cortex hemodynamics. “The commencement of the Kernel feasibility study marks a truly exciting moment, not only for Cybin and Kernel, but also for the entire field of psychedelic drug development. To this point, studies have had to rely on subjective patient reporting,” said Cybin CEO Doug Drysdale. “By deploying the innovative Flow technology,…

TuesdayMar 29, 2022 12:14 pm

QualityStocksNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Significant Milestone Toward Advancing CYB003 Program

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced the completion of in vivo preclinical studies evaluating its deuterated psilocybin analog CYB003 for the potential treatment of major depressive disorder (“MDD”). According to the update, data from the studies demonstrate that CYB003 is well-tolerated following several doses in multiple species and support the advancement toward an investigational new drug (“IND”) filing with the U.S. Food and Drug Administration (“FDA”) for a Phase 1/2a first-in-human clinical trial in patients with MDD. “The completion of these in vivo preclinical studies for CYB003 represents a…

FridayMar 25, 2022 10:56 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Subsidiary Achieves Milestone Outlined in Contribution Agreement

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has announced that its wholly controlled subsidiary, Adelia Therapeutics Inc., has achieved a key milestone. The milestones were identified in the Dec. 4, 2020, contribution agreement between Cybin and Adelia and include Year 1 Q4 (vi), Year 2 Q2 (ii), Year 2 Q2 (v) and Year 2, Q3 (iii). Others involved in the agreement include Cybin Corp., Cybin US Holdings Inc. and the previous shareholders of Adelia. According to the agreement, Adelia shareholders will be issued 90,546.0 Class B shares in Cybin; those shares are exchangeable…

ThursdayMar 24, 2022 2:11 pm

QualityStocksNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Commences Participant Recruitment in Feasibility Study Using Kernel Flow Technology

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that its company-sponsored feasibility study using Kernel’s quantitative neuroimaging technology, Kernel Flow, is actively recruiting participants. The study will evaluate participants’ experience wearing Kernel Flow while in an altered state of consciousness following the administration of ketamine. “The feasibility study using Kernel Flow offers an opportunity for researchers and our study participants to quantifiably gather information on a psychedelic experience,” Cybin’s Chief Executive Officer Doug Drysdale said in the press release. “Until now, our understanding of the psychedelic experience has been fairly subjective.…

ThursdayMar 24, 2022 9:15 am

Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Is a Leader in Psychedelic-Based Therapies; Recent Preclinical Research Shows Treatment Effective for MDD

Study shows that substantial antidepressant effects of psilocybin-based treatment, given with supportive psychotherapy, may last at least a year. Psilocybin could lead to significant, durable improvements in depression. Cybin is focused on improving overall mental health through psychedelic-based therapies. Johns Hopkins Medicine researchers have released a report noting that psilocybin treatment for major depression is effective for up to a year for many patients (https://ibn.fm/ZF8jH). That bodes well for Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company that is focused on revolutionizing mental health care, including major depressive disorder (“MDD”). “Previous studies by Johns Hopkins Medicine researchers…

Site Search

Company Search

Tag: Cybin Inc. CYBN